[Congressional Record Volume 167, Number 91 (Tuesday, May 25, 2021)]
[Senate]
[Page S3456]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 2020. Mr. BOOKER submitted an amendment intended to be proposed to 
amendment SA 1502 proposed by Mr. Schumer to the bill S. 1260, to 
establish a new Directorate for Technology and Innovation in the 
National Science Foundation, to establish a regional technology hub 
program, to require a strategy and report on economic security, 
science, research, innovation, manufacturing, and job creation, to 
establish a critical supply chain resiliency program, and for other 
purposes; which was ordered to lie on the table; as follows:

        At the end of subtitle A of title II of division C, insert 
     the following:

     SEC. 3219L. FRAMEWORK FOR DISTRIBUTION OF COVID-19 VACCINES 
                   AROUND THE WORLD.

       (a) In General.--Not later than 30 days after the date of 
     enactment of this Act, and every 30 days thereafter until the 
     date that is one year after such date of enactment, the 
     COVID-19 Task Force shall submit to the Committee on Foreign 
     Relations, the Committee on Appropriations, and the Committee 
     on Health, Education, Labor, and Pensions of the Senate, and 
     to the Committee Foreign Affairs, the Committee on 
     Appropriations, and the Committee on Energy and Commerce of 
     the House of Representatives a report on the framework for 
     the distribution around the world of COVID-19 vaccines 
     produced in the United States.
       (b) Content.--The reports submitted under subsection (a) 
     shall include updates, as appropriate, on the following:
       (1) The number of vaccines procured by the United States 
     and distributed through COVAX or through other bilateral or 
     multilateral agreements.
       (2) The number of vaccines procured by the United States 
     that the Federal Government has allocated for potential 
     future distribution through COVAX or through other bilateral 
     or multilateral agreements.
       (3) A framework for how countries will be prioritized for 
     the delivery of COVID-19 vaccines provided directly by the 
     Federal Government.
       (4) A review of deployments of health and diplomatic 
     personnel overseas engaged in COVID-19 response efforts.
                                 ______